Silvercrest Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.4M Sell
99,244
-10,115
-9% -$745K 0.05% 382
2026
Q2
$6.99M Sell
109,359
-4,930
-4% -$256K 0.05% 406
2026
Q1
$5.5M Sell
114,289
-12,120
-10% -$537K 0.04% 408
2025
Q4
$5.21M Buy
126,409
+149
+0.1% +$5.98K 0.04% 424
2025
Q3
$4.9M Buy
+126,260
New +$4.1M 0.03% 428

Other funds holding KNSA

Silvercrest Asset Management's KNSA Position: Q3 2026 in Review

Silvercrest Asset Management reduced its Kiniksa Pharmaceuticals (KNSA) stake by 9.2% in Q3 2026, selling an estimated $745K and leaving 99,244 shares worth $7.4M. The position accounts for 0.05% of the portfolio, ranked #382.

Silvercrest Asset Management first reported a position in KNSA in Q3 2025 and has held it in 5 quarters since. 305 funds tracked by Wall St. Rank hold KNSA as of Q3 2026.

  • Silvercrest Asset Management held 99,244 shares of Kiniksa Pharmaceuticals worth $7.4M as of Q3 2026.
  • Silvercrest Asset Management sold 10,115 Kiniksa Pharmaceuticals shares in Q3 2026, an estimated $745K.
  • Kiniksa Pharmaceuticals made up 0.05% of Silvercrest Asset Management's portfolio in Q3 2026, its #382 holding.
  • Silvercrest Asset Management first reported a position in Kiniksa Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • 305 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2026.

Based on Silvercrest Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.